Tenofovir Effectively Treats Adolescents With Chronic HBV

Once-daily tenofovir treatment is effective and well tolerated, regardless of prior treatment

FRIDAY, Dec. 14 (HealthDay News) -- In adolescents infected with hepatitis B virus (HBV), once-daily tenofovir treatment for 72 weeks effectively suppresses HBV DNA and normalizes alanine aminotransferase (ALT) values, regardless of prior HBV treatment exposure, according to research published in the December issue of Hepatology.

Karen F. Murray, M.D., of the University of Washington School of Medicine in Seattle, and colleagues conducted a randomized, placebo-controlled trial involving 106 adolescents aged 12 to <18 years with chronic hepatitis B (CHB) infection who received either tenofovir disoproxil fumarate (DF; 52 adolescents) or placebo (54 adolescents) once daily for 72 weeks.

The researchers found that 89 percent of tenofovir-treated patients achieved a virologic response, defined as HBV DNA <400 copies/mL, compared with none of the placebo-treated patients. Response to treatment was not affected by prior HBV treatment. Over the 72-week study trial period, no tenofovir resistance was observed. For patients with ALT levels above the upper limit of normal at baseline, levels normalized in 74 percent of tenofovir-treated patients and 31 percent of placebo-treated patients. However, grade 3 and 4 adverse events were more common in tenofovir- compared with placebo-treated patients (24 versus 10 percent). At week 72, no patients met the safety end point (6 percent decrease in spine bone mineral density).

"In conclusion, tenofovir DF therapy in HBV-infected adolescents was well tolerated and highly effective at suppressing HBV DNA and normalizing ALT values in both treatment-naive patients and those with prior exposure to oral HBV therapy," the authors write. "Tenofovir DF is, therefore, a valuable treatment option for the management of CHB in adolescents."

Several authors disclosed financial ties to pharmaceutical companies, including Gilead Sciences, which sponsored the study and markets tenofovir.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles

Dogs as Pets, Visitors, Therapists and Assistants
Home Healthcare Nurse, November/December 2014
Free access will expire on January 5, 2015.


Tracheostomy Care
Nursing2014 Critical Care, November 2014
Free access will expire on December 22, 2014.


Effective management of ARDS
The Nurse Practitioner, 13December 2014
Free access will expire on December 22, 2014.


More Recommended Articles

Subscribe to Recommended Articles

Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events